JP2023509463A - 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物 - Google Patents

細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物 Download PDF

Info

Publication number
JP2023509463A
JP2023509463A JP2022541285A JP2022541285A JP2023509463A JP 2023509463 A JP2023509463 A JP 2023509463A JP 2022541285 A JP2022541285 A JP 2022541285A JP 2022541285 A JP2022541285 A JP 2022541285A JP 2023509463 A JP2023509463 A JP 2023509463A
Authority
JP
Japan
Prior art keywords
chitosan
particles
therapeutic agent
therapeutic
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022541285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509463A5 (https=
Inventor
ナザリ ゴールドバーグ マニジェー
エム．マンジー アーロン
ゴールドバーグ エリック
ケー．ハリス マイケル
Original Assignee
プリボ テクノロジーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリボ テクノロジーズ，インコーポレイティド filed Critical プリボ テクノロジーズ，インコーポレイティド
Publication of JP2023509463A publication Critical patent/JP2023509463A/ja
Publication of JP2023509463A5 publication Critical patent/JP2023509463A5/ja
Priority to JP2025153243A priority Critical patent/JP2025178320A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022541285A 2020-01-03 2021-01-03 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物 Pending JP2023509463A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153243A JP2025178320A (ja) 2020-01-03 2025-09-16 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062956795P 2020-01-03 2020-01-03
US62/956,795 2020-01-03
PCT/US2021/012015 WO2021138646A1 (en) 2020-01-03 2021-01-03 Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153243A Division JP2025178320A (ja) 2020-01-03 2025-09-16 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物

Publications (2)

Publication Number Publication Date
JP2023509463A true JP2023509463A (ja) 2023-03-08
JP2023509463A5 JP2023509463A5 (https=) 2024-01-11

Family

ID=76687575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022541285A Pending JP2023509463A (ja) 2020-01-03 2021-01-03 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物
JP2025153243A Pending JP2025178320A (ja) 2020-01-03 2025-09-16 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153243A Pending JP2025178320A (ja) 2020-01-03 2025-09-16 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物

Country Status (9)

Country Link
US (1) US20230103552A1 (https=)
EP (1) EP4084828A4 (https=)
JP (2) JP2023509463A (https=)
KR (1) KR20220125798A (https=)
CN (2) CN121421961A (https=)
AU (1) AU2021204918A1 (https=)
BR (1) BR112022013270A2 (https=)
CA (1) CA3166633A1 (https=)
WO (1) WO2021138646A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015172A1 (en) 2016-02-18 2017-08-24 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
KR20240041285A (ko) 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
KR20250123284A (ko) 2024-02-07 2025-08-18 순천향대학교 산학협력단 클릭화학을 이용한 약물 봉입 엑소좀 유사체의 제조 방법 및 약물 봉입 엑소좀 유사체
CN121221639A (zh) * 2025-10-11 2025-12-30 中山大学附属第五医院 一种负载难溶性中药小分子阿可拉定hp@ict水凝胶、及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190388356A1 (en) * 2016-02-18 2019-12-26 Privo Technologies, Inc. Two-Stage Microparticle-Based Therapeutic Delivery System and Method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
AU2001253334A1 (en) 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
MX2007003789A (es) * 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
US7867984B1 (en) * 2005-01-04 2011-01-11 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8242165B2 (en) * 2006-10-26 2012-08-14 Creighton University Mucoadhesive nanoparticles for cancer treatment
ES2562878T3 (es) * 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
WO2009158145A2 (en) * 2008-05-30 2009-12-30 Allergan, Inc. Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form
EP2306991B1 (en) * 2008-06-27 2019-12-25 Tepha, Inc. Injectable delivery of microparticles and compositions therefore
US20170136127A1 (en) * 2014-07-01 2017-05-18 Vicus Therapeutics, Llc Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
WO2018151849A1 (en) * 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) * 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190388356A1 (en) * 2016-02-18 2019-12-26 Privo Technologies, Inc. Two-Stage Microparticle-Based Therapeutic Delivery System and Method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOMATERIALS, vol. 33, JPN6024047585, 2012, pages 3909 - 318, ISSN: 0005591973 *
JOUNAL OF CONTROLLED RELEASE, vol. 126, JPN6024047584, 2008, pages 205 - 216, ISSN: 0005591974 *
JOURNAL OF NANOTECHNOLOGY IN ENGINEERING AND MEDICINE, vol. Vol.5, 040905, JPN6024047586, 2014, pages 1 - 11, ISSN: 0005591971 *

Also Published As

Publication number Publication date
BR112022013270A2 (pt) 2022-09-06
CN115243722A (zh) 2022-10-25
KR20220125798A (ko) 2022-09-14
CN121421961A (zh) 2026-01-30
AU2021204918A1 (en) 2022-07-21
CA3166633A1 (en) 2021-07-08
US20230103552A1 (en) 2023-04-06
EP4084828A4 (en) 2024-03-13
JP2025178320A (ja) 2025-12-05
WO2021138646A1 (en) 2021-07-08
EP4084828A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
JP2023509463A (ja) 細胞の標的集団の直接注射による治療のためのシステム及び医薬組成物
CN110917345B (zh) 一种化疗免疫组合药物及其制备方法
KR102203555B1 (ko) 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
Ta et al. Injectable chitosan hydrogels for localised cancer therapy
Nagahama et al. Self-assembling polymer micelle/clay nanodisk/doxorubicin hybrid injectable gels for safe and efficient focal treatment of cancer
Liang et al. Injectable nanocomposite hydrogels improve intraperitoneal co-delivery of chemotherapeutics and immune checkpoint inhibitors for enhanced peritoneal metastasis therapy
CN112438944B (zh) 一种治疗肿瘤的温敏型凝胶药物组合物
Luo et al. Preparation, thermal response mechanisms and biomedical applications of thermosensitive hydrogels for drug delivery
AU2013370955A1 (en) Nanoparticle compositions of albumin and paclitaxel
US20240041781A1 (en) Two-stage microparticle-based therapeutic delivery system and method
US11938186B2 (en) Thermosensitive hydrogel for cancer therapeutics and methods of preparation thereof
US12589080B2 (en) Enhanced two-stage microparticle-based localized therapeutic delivery system
Bagheri et al. Injectable hydrogels for intratumoral administration against breast cancer
CN104940138A (zh) 一种刺激敏感型透明质酸原位凝胶的制备方法
CN113840594A (zh) 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
KR101898816B1 (ko) 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템
Chen et al. Hydrogel-Based intraperitoneal drug delivery platforms for peritoneal metastasis: strategies, advances, and prospects
US20230248642A1 (en) Injectable high-drug-loaded nanocomposite gels and process for making the same
Kumar et al. Localized delivery of bioactives using structured liposomal gels
Tayebi-Khorrami et al. Immune checkpoint blocking in cancer therapy using thermosensitive hydrogels: a review
AC Manoukian et al. Polymeric nanoparticles to combat squamous cell carcinomas in patients with dystrophic epidermolysis bullosa
US20240226027A1 (en) Pharmaceutical composition in the form of an injectable nanocomposite gel for co-delivery of multiple medicines or drugs
CN114681613B (zh) 一种原位成胶化疗免疫药物组合物及其制备方法
Zeng et al. Research Strategies and Methods of Hydrogels for Antitumor Drug Delivery. Biomedicines 2025, 13, 1899
CN114010592B (zh) 一种可瘤内或瘤周注射的咪喹莫特混悬液制剂及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250513